Clinical Trial Update: A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor [Phase 3]

View source ↗

Summary

A Phase 3 multinational trial evaluating BPS-314d-MR for pulmonary arterial hypertension has been withdrawn; no study results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• BPS-314d-MR

Snippet

Sponsor: Lung Biotechnology PBC | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN